Annual Report 2019

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2019 88 The United Laboratories International Holdings Limited Annual Report 2019 5. REVENUE AND SEGMENT INFORMATION (Continued) Segment information HKFRS 8 Operating Segments requires operating segments to be identified on the basis of internal reports about components of the Group that are regularly reviewed by the chief operating decision maker (“CODM”) (i.e. executive directors of the Company) for the purpose of allocating resources to segments and assessing their performance. The three revenue streams are the operating and reportable segments of the Group on which the Group reports its primary segment information. (a) Segment revenue and results: Year ended 31 December 2019 Intermediate Bulk Finished Segment products medicine products total Elimination Consolidated RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 REVENUE External sales 1,280,352 3,593,112 3,519,136 8,392,600 – 8,392,600 Inter-segment sales 1,516,838 533,695 – 2,050,533 (2,050,533) – Segment revenue 2,797,190 4,126,807 3,519,136 10,443,133 (2,050,533) 8,392,600 RESULT Segment profit 87,344 235,943 783,500 1,106,787 Unallocated other income 108,873 Unallocated corporate expenses (98,522) Other gains and losses, net 12,638 Loss on fair value change of embedded derivative components of convertible bonds (110,117) Gain on disposal of a subsidiary 200,445 Loss on fair value change on investment properties (97,614) Finance costs (280,838) Profit before taxation 841,652